Miranda has 15 years of academic and industry experience in the field of pluripotent stem cells, iPS reprogramming, and differentiation. She supports ElevateBio’s efforts to generate clinical grade induced pluripotent stem cell (iPSC) lines and novel stem cell therapies.
Prior to ElevateBio, Miranda led R&D efforts to develop new products and applications for drug discovery and liver-related research at BioIVT. Before BioIVT, Miranda worked at a number of stem cell companies, including Stemgent and ESI BIO/BioTime, developing integration-free reprogramming systems as well as stem cell research products. Miranda received her postdoctoral training at Harvard Stem Cell Institute, where she developed and executed small molecule screens employing iPSC-derived neurons and high-content imaging-based assays that identified novel therapeutic targets for ALS.
Education & Accomplishments
Miranda holds a PhD from University of Rochester, NY, where she studied the toxic effects of chemotherapeutics on the adult brain.
Interested in working with people like Miranda? We’re looking for pioneers and innovative thinkers committed to developing the next-generation of cell and gene therapies. Review our open roles and find your future.